Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Leukemia, B-Cell 2Leukemia 2Hematologic Diseases 2Bronchiolitis Obliterans Syndrome 2Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, B-Cell 1Lymphoma 1Immunoproliferative Disorders 1Immune System Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 14fludarabine 9fludarabine phosphate 8Busulfan 5Bendamustine Hydrochloride 5Tacrolimus 4Rituximab 4Mycophenolic Acid 4ibrutinib 3Melphalan 3Bortezomib 3AP 1903 reagent 3tetulomab tetraxetan lu-177 2ponatinib 2pembrolizumab 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bone Marrow Transplantation 2thymoglobulin 1pimonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune System Diseases × KW-2478 × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡